- Home
- SNSE vs IMRN Comparison
SNSE vs IMRN Comparison
Compare SNSE & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNSE
- IMRN
- Stock Information
- Founded
- SNSE 2005
- IMRN 1994
- Country
- SNSE United States
- IMRN Australia
- Employees
- SNSE N/A
- IMRN N/A
- Industry
- SNSE Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- SNSE Health Care
- IMRN Health Care
- Exchange
- SNSE Nasdaq
- IMRN Nasdaq
- Market Cap
- SNSE 12.5M
- IMRN 15.0M
- IPO Year
- SNSE 2021
- IMRN N/A
- Fundamental
- Price
- SNSE $0.45
- IMRN $1.90
- Analyst Decision
- SNSE Strong Buy
- IMRN Strong Buy
- Analyst Count
- SNSE 3
- IMRN 1
- Target Price
- SNSE $4.33
- IMRN $5.00
- AVG Volume (30 Days)
- SNSE 168.7K
- IMRN 4.9K
- Earning Date
- SNSE 03-03-2025
- IMRN 03-03-2025
- Dividend Yield
- SNSE N/A
- IMRN N/A
- EPS Growth
- SNSE N/A
- IMRN N/A
- EPS
- SNSE N/A
- IMRN N/A
- Revenue
- SNSE N/A
- IMRN $3,271,194.00
- Revenue This Year
- SNSE N/A
- IMRN N/A
- Revenue Next Year
- SNSE N/A
- IMRN N/A
- P/E Ratio
- SNSE N/A
- IMRN N/A
- Revenue Growth
- SNSE N/A
- IMRN 171.67
- 52 Week Low
- SNSE $0.38
- IMRN $1.65
- 52 Week High
- SNSE $1.94
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- SNSE 38.52
- IMRN 43.76
- Support Level
- SNSE $0.44
- IMRN $1.89
- Resistance Level
- SNSE $0.49
- IMRN $2.05
- Average True Range (ATR)
- SNSE 0.04
- IMRN 0.08
- MACD
- SNSE -0.00
- IMRN -0.02
- Stochastic Oscillator
- SNSE 10.73
- IMRN 3.85
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.